06/07/23 8:30 AMNasdaq : GPCR low floatStructure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific SessionsStructure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that clinical and preclinicalRHEA-AIneutral
05/31/23 4:30 PMNasdaq : GPCR conferenceslow floatStructure Therapeutics to Present at Jefferies Healthcare ConferenceStructure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that Raymond Stevens, Ph.D., theRHEA-AIneutral
05/25/23 4:30 PMNasdaq : GPCR clinical triallow floatStructure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and formulation bridging study planned to evaluate tablet formulation in preparation for global Phase 2bRHEA-AIneutral
05/18/23 4:30 PMNasdaq : GPCR low floatStructure Therapeutics Announces Poster Presentations at the American Thoracic Society International ConferenceStructure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage globalRHEA-AIneutral
05/11/23 4:30 PMNasdaq : GPCR earningslow floatStructure Therapeutics Reports First Quarter 2023 Financial Results and Recent HighlightsStructure Therapeutics Inc.RHEA-AIneutral
03/30/23 4:30 PMNasdaq : GPCR earningslow floatStructure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent HighlightsStructure Therapeutics Inc.RHEA-AIneutral
02/07/23 4:00 PMNasdaq : GPCR IPOofferinglow floatStructure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary SharesStructure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the closing of its previouslyRHEA-AIneutral
02/04/23 12:15 AMNasdaq : GPCR, SDGR low floatQiming Venture Partners Backed Structure Therapeutics Successfully Debuts on NasdaqQiming Venture Partners' portfolio company Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical stage global biopharmaceutical company focusing on novel oral small molecule therapeutics, successfully debuts on Nasdaq on February 3 Beijing Time. It issued atRHEA-AIvery positive
02/02/23 7:41 PMNasdaq : GPCR IPOofferinglow floatStructure Therapeutics Announces Pricing of Upsized Initial Public OfferingStructure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the pricing of its upsizedRHEA-AIneutral